中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells

文献类型:期刊论文

作者Liu, Yuwei1,2; Xue, Mengzhu1; Cao, Danyan2; Qin, Lihuai3; Wang, Ying2; Miao, Zehong2; Wang, Peng4; Hu, Xin5; Shen, Jingkang2; Xiong, Bing2
刊名GENOMICS
出版日期2021-05-01
卷号113期号:3页码:1057-1069
关键词Multi-omics BET inhibitor responses WNT pathway Liver cancer Precise therapy
ISSN号0888-7543
DOI10.1016/j.ygeno.2021.02.017
通讯作者Xue, Mengzhu(xuemz@sari.ac.cn) ; Wang, Peng(wangpeng@picb.ac.cn) ; Hu, Xin(xinhu@fudan.edu.cn) ; Xiong, Bing(bxiong@simm.ac.cn)
英文摘要The Bromodomain and Extra-terminal domain (BET) proteins are promising targets in treating cancers. Although BET inhibitors have been in clinical trials, they are limited by lacking of suitable biomarkers to indicate drug responses in different cancers. Here we identify DHRS2, ETV4 and NOTUM as potential biomarkers to indicate drug resistance in liver cancer cells of a recently discovered BET inhibitor, Hjp-6-171. Furthermore, we confirm that reactivation of WNT pathway, the target of NOTUM, contributes to the drug sensitivity restoration in Hjp-6171 resistant cells. Specially, combinations of Hjp-6-171 and a GSK38 inhibitor CHIR-98014 show remarkable therapeutic effects in vitro and in vivo. Integrating RNA-seq and ChIP-seq data, we reveal the expression signature of 8-catenin regulated genes is contrary in sensitive cells to that in resistant cells. We propose WNT signaling molecules such as 8-catenin and ETV4 to be candidate biomarkers to indicate BET inhibitor responses in liver cancer patients.
WOS关键词WNT/BETA-CATENIN PATHWAY ; HEPATOCELLULAR-CARCINOMA ; BREAST-CANCER ; GROWTH ; ACTIVATION ; SCALE ; NOTUM ; DHRS2 ; DKK1
资助项目Science and Technology Commission of Shanghai Municipality Project[16ZR1449000] ; National Natural Science Foundation of China (NSFC)[31701154] ; National Natural Science Foundation of China (NSFC)[81330076] ; National Science & Technology Major Project Key New Drug Creation and Manufacturing Program of China[2018ZX09711002-011-018]
WOS研究方向Biotechnology & Applied Microbiology ; Genetics & Heredity
语种英语
WOS记录号WOS:000661250200006
出版者ACADEMIC PRESS INC ELSEVIER SCIENCE
源URL[http://119.78.100.183/handle/2S10ELR8/297114]  
专题中国科学院上海药物研究所
通讯作者Xue, Mengzhu; Wang, Peng; Hu, Xin; Xiong, Bing
作者单位1.Chinese Acad Sci, Shanghai Adv Res Inst, SARI Ctr Stem Cell & Nanomed, Shanghai 201210, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
3.Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, Ctr Chem Biol & Drug Discovery, New York, NY 10029 USA
4.Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Biomed Big Data Ctr,Key Lab Computat Biol, Shanghai 200031, Peoples R China
5.Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
推荐引用方式
GB/T 7714
Liu, Yuwei,Xue, Mengzhu,Cao, Danyan,et al. Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells[J]. GENOMICS,2021,113(3):1057-1069.
APA Liu, Yuwei.,Xue, Mengzhu.,Cao, Danyan.,Qin, Lihuai.,Wang, Ying.,...&Xiong, Bing.(2021).Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells.GENOMICS,113(3),1057-1069.
MLA Liu, Yuwei,et al."Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells".GENOMICS 113.3(2021):1057-1069.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。